GlioResolve

Funded by the European Union

HORIZON - MSCA Doctoral Network

10 New PhD Student Positions

Applications are invited from candidates of excellence wishing to pursue a PhD degree in the field of cancer precision medicine.

The pan-European, academic & private sector GLIORESOLVE Doctoral Network, which comprises 10 funded beneficiaries and 11 associated partner organisations representing 10 countries, seeks to train 10 innovative, creative and entrepreneurial PhD students over 3 years, with a specific focus on brain tumour research.

Glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required.

The overall research objective of GLIORESOLVE is to leverage a novel GBM tumour microenvironment (TME) classification system (developed during the recently completed Gliotrain Project), to establish new therapeutic strategies for GBM. Key outcomes expected from GLIORESOLVE are (1) to extend immunotherapy options to GBM patients and identify novel TME-subtype-specific therapeutic targets, (2) develop and optimise state of the art pre-clinical models that recapitulate GBM TME-subtypes and (3) test novel rationally selected (available) drugs / drug combinations for precision treatment of GBM based on TME-subtype assignment.

The consortium brings together leading European academics, clinicians, private sector and not-for-profit partners, and incorporates disruptive research methods including multi-omics, ex-vivo 'tumour-on-a-chip' assay development, computational modelling and systems biology.

Thus, GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease. Moreover, the Doctoral Network addresses current needs in academia and the private sector to train PhD researchers in an environment that spans multiple disciplines. GLIORESOLVE candidates will be able to

navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Funding:

This project receives funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie Doctoral Networks grant agreement No 101073386 (GLIORESOLVE).

Researcher Salary:

Selected PhD candidates will be offered a competitive salary in line with MSCA funding rules. This includes a monthly living allowance of c. €3,400 (this is a variable amount, based on an automatically calculated adjustment assuming the expected cost of living in the country of recruitment), and a monthly mobility allowance of €600. Additional allowances (also paid as salary) are available to candidates with family commitments (€660 per month) and, where required, to those with disabilities. **Please note that all compulsory national contributions (social security, pension, insurances, taxes etc.) to be borne by the employer and employee shall be deducted from the abovementioned amounts** in line with MCSA Rules. These deductions vary between countries and institutes. Please refer to each project description for putative gross salary details for each position. Gross salary reflects the EU adjustments for living allowance.

Candidate requirements:

- Can be of any nationality, but are required to undertake transnational mobility as per the mobility rule (see below).
- Should ideally possess a Master's degree in a relevant academic field, however exceptional candidates holding a Bachelor's degree will be considered.
  Applications from candidates who already possess a doctoral degree will not be considered.
- Must be willing to travel (candidates must spend time on secondments in academic, clinical and/or private sector research institutions and must be willing to travel to organised training events over the course of the project).
- Should be able to demonstrate motivation and a strong eagerness to learn.
- Possess excellent written, oral communication and organisational skills.
- Should have the ability both to work independently and as part of a team.
- Previous related research experience will be a distinct advantage.
- Must be able to commence on the project by April 2023.

Mobility Rule:

At the date of recruitment, the candidate must not have resided or carried out their main activity (work, studies, etc.) in the country of their recruiting organisation for more than 12 months in the previous 3 years. Short stays such as holidays and/or compulsory national service are not taken into account.

Application process:

Applicants should submit a full CV and motivation letter, which details the following:

- Up to three projects that they would like to apply for (see below).
- Description of previous research experiences.
- Contact details or recommendation letters of two referees.
- Proof of English language proficiency where required.

Only documents in English will be accepted. Documents should be submitted to glioresolve@rcsi.ie writing in the subject line the number of the selected projects (E.g. "Projects 1 and 3") no later than 18:00 CET on December 23rd 2022.

Selection process:

Shortlisted candidates will be invited for online interviews in the first instance and may be invited for subsequent in-person interviews. Interviews will commence in January 2023. Positions will be offered to candidates following approval by the GLIORESOLVE co-ordinator and supervisory board. We will endeavour to provide feedback to unsuccessful applicants where possible.

Working conditions:

- Recruited candidates will be Marie Skłodowska-Curie fellows and will have rights associated with this.
- The candidates will be recruited by GLIORESOLVE Beneficiaries and will be hosted at the premises of the Beneficiary.
- Personal Career Development Plans will be established and developed during the project.
- Each successful candidate will work on an individual research project and will undertake inter-sectoral secondments.
- Where projects extend beyond three years, PhD candidates will be supported using alternative funds. Salary and terms and conditions of employment will be in line with individual Institutional policies.

Informal Inquires:

For informal inquiries regarding the application and eligibility questions, contact glioresolve@rcsi.ie. For informal queries regarding specific projects, contact the main supervisor directly.

Recruitment will be open, transparent, impartial, equitable and merit-based and in line with In line with the European Charter, and Code of Conduct for the Recruitment of Researchers.

GLIORESOLVE PhD Projects

Project 1: **Development of optimized oncolytic virus therapy for GBM TME subtypes**

Recruitment Location: Erasmus MC, Rotterdam, The Netherlands

Main Supervisor: Dr Martine Lamfers, Associate Professor in Experimental Neurooncology & Head of Neurosurgery Laboratory of the Erasmus MC Brain Tumour Center (m.lamfers@erasmusmc.nl)

Co-supervisors: Dr Yunlei Li (Erasmus MC), Prof Dr Antonio Chiocca, MD (Brigham and Women's Hospital, Boston, MA)

Additional collaborators: Dr Karla Queiroz (Mimetas BV, Leiden, The Netherlands)

Project Summary: The application of oncolytic viruses (OVs) is a promising immunotherapeutic approach in the GBM setting, however OV efficacy is highly variable among tumour (sub)types and hosts. Clinical trials testing OVs in GBM patients have consistently revealed a small percentage of long-term responder patients, with the majority failing to respond. Analysis of interactions between different OVs and host-specific TME profiles may yield insight into mechanisms underlying these outcomes. Recently, an ex vivo autologous peripheral blood mononuclear cells (PBMC)-GBM co-culture system was developed at EMC with the aim of monitoring OV immune-stimulatory effects on patient samples. This model also allows testing of strategies to boost OV efficacy. The PhD candidate will identify molecular signatures (RNAseq, Whole Genome Seq ([WGS]) to define optimal OV (combination) treatment for GBM TME subtypes.

Expected secondments:

- 6 months (academic) to the Brigham and Women's Hospital, Boston, MA, USA.
- 4 months (non-academic) to Mimetas BV, Leiden, The Netherlands.

Specific Requirements:

- MSc in a Biological Discipline with preference given to those candidates with experience in Tumour Biology/Oncology/Virology/Immunology.
- Experience in cell culture, *in vitro* model development, and flow cytometry.
- Experience with Next Generation Sequencing methods and analysis and bioinformatics.

EU salary budget: Living allowance - €134,150.40; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: **€45,000***. Please note that employee compulsory national contributions will be deducted from this amount. *(*This salary includes a top-up from available local funding and is a minimum expected salary.)*

Project 2: Evaluation of ultrasound-induced TME-subtype modulation in combination with ICIs in GBM

Recruitment Location: Paris Brain Institute (ICM), Paris, France

Main Supervisor: Prof Ahmed Idbaih, MD, PhD, Principle Investigator, Experimental neuro-oncology (ahmed.idbaih@aphp.fr)

Co-supervisors: Dr Maite Verreault (ICM), Dr Carole Desseaux (Carthera, Lyon, France)

Additional collaborators: Prof Annette Byrne (RCSI, Dublin, Ireland), Mr Frederic Sottilini (Carthera)

Project Summary: A strategy to alter the TME subtype in patients may sensitise tumours to immunotherapies. Low-intensity pulsed ultrasound (LIPU) is a safe and effective method to enhance therapeutic agents delivery to the brain, as reported in preclinical and clinical settings. Previously, ICM have shown that the efficacy of anti-PDL1 therapeutic antibody is enhanced when administered in combination with LIPU. ICM found that LIPU was able to increase the delivery of anti-PDL1 antibody to the brain and the tumour and to activate microglia cells. Most importantly, this combination doubled the number of long-term survivors compared to anti-PDL1 administration alone. The successful PhD candidate will expand this observation and evaluate the impact of LIPU on the efficacy of promising immune checkpoint inhibitors. Specifically, we hypothesize that LIPU administration will enhance the efficacy of anti-LAG3, anti-CD73, anti-galectin-9 and anti-TIM-3 by altering the composition and activation states of immune cell populations across TME subtypes, thus facilitating TME 'subtype switching'.

Expected secondments

- 3 months (non-academic) to Carthera, Lyon, France.
- 3 months (academic) to RCSI, Dublin, Ireland.

Specific Requirements:

- MSc in a Biological Discipline with preference given to those candidates with experience in Oncology and Immuno-oncology.
- Experience with Molecular biology, Cell culture, Flow cytometry methods and analysis.
- In vivo tumour model experience is mandatory for this position.

EU salary budget: Living allowance - €142,473.60; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: **€38,061**. Please note that employee compulsory national contributions will be deducted from this amount.

Project 3: Targeting the Treg – macrophage axis to promote immune stimulation and tertiary lymphoid structure formation in IDHwt GBM TME subtypes

Recruitment Location: Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium

Main Supervisor: Prof Gabriele Bergers, Professor of Oncology at the University of Leuven and a group leader at the VIB-Center for Cancer Biology (gabriele.bergers@kuleuven.be)

Co-supervisor: Dr Oliver Politz (Bayer AG, Berlin, Germany)

Additional collaborators: Prof Frederik De Smet (KU Leuven, Belgium)

Project Summary: GBMs comprise an intricate TME that displays angiogenic and vascular abnormalities, hypoxia and necrosis, poor T lymphocyte infiltration and abundance of myeloid cells. These phenotypes, together with the low tumour antigen burden, are responsible for the immunosuppressive milieu, which has made various immunotherapeutic strategies ineffective in clinical trials in GBM to date. VIB (alongside RCSI) have identified new TME subtypes which correlate inversely with the degree of blood-brain barrier (BBB) impairment. Angiogenic, BBB-impaired tumour vessels have been shown to hinder T-cell infiltration while T-regs and tumour-associated chemokine-secreting macrophages restrict the activity of effector T cells. Here, in order to sensitize GBMs to immunotherapy, the PhD candidate will assess the mechanistic underpinnings TME subtypes in GBM and tailor immune-modulating strategies in GBM mouse models according to TME subtype.

Expected secondments:

- 4 months (non-academic) to Bayer AG, Berlin, Germany.

Specific Requirements:

- MSc in a Biological Discipline with preference given to those candidates with experience in Oncology/Tumour Biology or Immunology.
- Experience with Sequencing and bioinformatics analysis are preferred.

EU salary budget: Living allowance - €122,400; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: **€50,500*** with increment after 2 years. Please note that employee compulsory national contributions will be deducted from this amount. *(*This salary includes a top-up from available local funding.)*

Project 4: Targetability of IDHwt GBM TME subtype – specific T cell and GBM associated endothelial cell interactome

Recruitment Location: Medical Faculty Mannheim, University of Heidelberg (UHEI), Germany

Main Supervisor: Prof Michael Platten, MD, Chairman of the Neurology Clinic, Medical Faculty Mannheim, Heidelberg University, Head of the Neuroimmunology and Brain Tumor Immunology department at UHEI and DKFZ and the Immune Monitoring Unit at National Center for Tumor Diseases (m.platten@Dkfz-Heidelberg.de)

Co-supervisors: Dr Lukas Bunse, MD, PhD (UHEI), Dr Andrzej Dzionek (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany)

Project Summary: Effective cellular immune responses in GBM are suppressed not only by heterogeneous glioma cells, but also by metabolites, chemokines secreted by, and direct interaction with stromal cells that have adapted to exhaustive or immunosuppressive glioma-associated states. T cells, the ultimate effector immune cell type required to eradicate solid tumours, are not only exhausted in GBM, but remain scarce in primary and post-treatment GBM. RCSI has proposed a novel subtype classification for GBM based on TME composition with the highest intratumoural abundance of T cells in the TME-high subtype. However, TME-high associated expression signatures of endothelial cells affecting the leukocyte–endothelial cell adhesion and transmigration axis remain unknown. The successful PhD candidate will perform unbiased analyses of TME-high-associated endothelial cell expression signatures that are correlated with enhanced intratumoural T cell abundance will provide novel strategies to improve trans-migratory capacities of engineered T cell or glioma-infiltrating leukocyte products to treat GBM.

Expected secondments:

- 4 months (non-academic) to Miltenyi Biotech, Bergisch Gladbach, Germany.

Specific Requirements:

- MSc in a Biological Discipline with preference given to those candidates with experience in Oncology/Tumour Biology or Immunology.
- Experience with single cell and bioinformatics analysis are preferred.
- Experience with (immune) cell engineering is preferred.

EU salary budget: Living allowance - €120,319.20; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: **€39,000**. Please note that employee compulsory national contributions will be deducted from this amount

Project 5: Patient-derived screening platform for probing personalized immunotherapies in TME-based GBM subtypes

Recruitment Location: Luxembourg Institute of Health (LIH), Luxembourg

Main Supervisor: Dr Anna Golebiewska, Head of the NORLUX Neuro-Oncology Laboratory, LIH (anna.golebiewska@lih.lu)

Co-supervisor: Prof Simone Niclou (LIH)

Additional collaborators: Dr Else M Inderberg (Oslo University Hospital (OUS), Norway), Dr Daniel Stieber (Laboratoire national de santé (LNS), Dudelange, Luxembourg)

Project Summary: Differences in GBM TME composition are linked to several factors including patient-specific genetic, epigenetic aberrations and TME cues in spatially-distributed tumour niches. The research field is currently hampered by a lack of appropriate preclinical models allowing for assessment of the crosstalk between tumour and immune cells. Immunocompetent patient-derived organoids (PDOs) (i.e. co-cultures of tumour organoids with immune cells from patient or donor blood) and patient-derived orthotopic xenografts (PDOXs) developed in humanised mice (i.e. containing a partially reconstituted human immune system) are currently the most promising models for investigating immunotherapies in a patient-specific manner. To this end, the successful candidate will exploit the large LIH collection of PDOs and PDOXs as a platform to develop and probe a precision immunotherapeutic strategy based on TME-based GBM subtypes.

Expected secondments:

- 3 months (non-academic) to LNS, Dudelange, Luxembourg.
- 2 months (academic) to OUS, Oslo, Norway.

Specific requirements:

- Master in Biological Sciences, ideally with a focus on cancer biology or immunology.
- Strong background in cellular and molecular biology.
- Affinity to omics data and bioinformatics is a plus.

EU salary budget: Living allowance - €122,400; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: **€41,429** (Year 1), €42,811 (Year 2), €43,881 (Year 3). Please note that employee compulsory national contributions will be deducted from this amount.

Project 6: Establishment of GBM TME subtypes-on-chip models

Recruitment Location: Mimetas BV, Oegstgeest, The Netherlands

Main Supervisor: Dr Karla Queiroz, Senior Scientist in Application Development, Mimetas BV (k.queiroz@mimetas.com)

Co-supervisors: Dr Todd Burton (Mimetas BV), Dr Henriette Lanz (Mimetas BV), Dr Martine Lamfers (Erasmus MC)

Project Summary: Major advances in organ-on-a-chip (OoaC) technology in GBM have increased our understanding of disease pathogenesis, however current OoaC models still lack the level of complexity as is observed in patients. The successful candidate will develop and validate a novel patient-derived "GBM on-a-chip" model assay that recapitulates the GBM TME subtypes. This model will be used for testing efficiency of novel immunotherapeutic strategies.

Expected secondments:

- 4 months (academic) to Erasmus MC, Rotterdam, The Netherlands.
- 6 months (academic) to RCSI, Dublin, Ireland.

Specific requirements:

- MSc in a Biology/Bioengineering or a related discipline with preference given to those candidates with experience in Tumour Biology/Oncology/immunology.
- Experience with Molecular biology, Cell culture, Flow cytometry methods and analysis.
- Experience with in vitro tumour modelling as well as omics data analysis and bioinformatics is a plus.

EU salary budget: Living allowance - €134,150.40; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: c. **€39,000** (minimum) with increment. Please note that employee compulsory national contributions will be deducted from this amount.

Project 7: Identification of novel TME subtype-specific treatments for IDHwt GBM

UNIVERSITY OF MEDICINE AND HEALTH SCIENCES
RCSI

Recruitment Location: Royal College of Surgeons in Ireland (RCSI Dublin City Centre Campus)

Main Supervisors: Prof Annette Byrne (annettebyrne@rcsi.ie) & Prof Jochen Prehn (jprehn@rcsi.ie) (Physiology and Medical Physics, RCSI)

Co-supervisors: Dr Oliver Politz (Bayer AG), Dr Kieron Sweeney, MD (RCSI)

Project Summary: The successful candidate will apply transcriptome-based gene signatures, bioinformatics (Gene Ontology (GO) of biological processes enrichment and KEGG pathway analysis) as well as statistical and network modelling approaches to analyse signalling pathways across newly identified GBM TME subtypes. Available WGS, RNAseq, RPPA, methylation and clinical data from external cohorts will be studied to provide functional insights into phenotypic subtype heterogeneity. These data analysis approaches will be further employed to identify novel contexts of vulnerability and novel treatment approaches, which will be tested in subtype-specific syngeneic in vivo tumour models. Tissue from these in vivo studies will further undergo in-depth spatial transcriptomics analysis to explore treatment response mechanisms.

Expected secondments:

- 6 months (non-academic) to Bayer AG, Berlin, Germany.

Specific Requirements:

- MSc or BSc in Bioinformatics / Human Genetics / (Bio)Engineering or a related discipline with preference given to those candidates with experience in Tumour Biology/Oncology.
- Experience with Analysis of Genomics Data / Next Generation Sequencing (RNA Seq, Shallow Sequencing etc.) or Proteomics data.
- Programming skills and/or Statistical Analysis Methods are of advantage.
- In Vivo Tumour Model experience *preferred.*

EU salary budget: Living allowance - €146,268.00; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: **€46,763**. Please note that employee compulsory national contributions will be deducted from this amount.

Project 8: Modelling therapeutic resistance in GBM TME subtypes using multiomics computational models

Recruitment Location: geneXplain, Wolfenbüttel, Germany

Main Supervisor: Prof Dr Edgar Wingender, CEO of GeneXplain and Professor for bioinformatics and director of the Institute of Bioinformatics at the University Medical Center Göttingen (edgar.wingender@genexplain.com)

Co-supervisors: Dr Alexander Kel (GeneXplain), Prof Jochen Prehn (RCSI)

Project Summary: Modelling the mechanisms of signalling and feedback loops between various cell types of the GBM TME and tumour cells will elucidate key components of the interaction network to predict novel therapeutic targets and biomarkers across the TME subtypes. The GEX platform integrates statistical, bioinformatics and systems biological modules with manually curated knowledge based on transcription factors and their binding sites (TRANSFAC® - gold standard in the field), and an in-depth database on intracellular signal transduction networks (TRANSPATH™). During GLIORESOLVE a new level of modelling will be introduced to the platform to support modelling of cytokine/chemokine interactions between tumour and TME in the TME subtypes. The successful candidate will interrogate TME-subtype specific interaction networks and identify TME-subtype specific master regulators and drug targets.

Expected secondments:

- 6 months (academic) to RSCI, Dublin, Ireland.

Specific requirements:

- MSc in Mathematics/Computer science or Bioinformatics.
- Experience with analysis of multi-omics data, upstream analysis, pathway analysis using on-line tools that integrate analysis of genomic regulatory motifs and signalling and gene regulatory networks.
- Experience with modelling, AI/machine learning or computer linguistics.
- Fluent written and spoken English, excellent oral communication skills and organizational skills. Interest in entrepreneurship and interaction of science and business. Interest and experience in online promotion of scientific products and knowledge, including experience in social media channels management.

EU salary budget: Living allowance - €120,319.20; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: **€37,998**. Please note that employee compulsory national contributions will be deducted from this amount.

Project 9: Mapping the therapeutic potential of Ag5 and its effects on the TME using a multi-omics approach in IDHwt GBM patient derived models

Recruitment Location: KU Leuven, Belgium

Main Supervisor: Prof Frederik De Smet, Head of the Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging and Pathology, KU Leuven (frederik.desmet@kuleuven.be)

Co-supervisor: Dr Martin Treder (Arjuna Therapeutics S.L, A Coruña, Spain)

Project Summary: Recently, Ag5 was identified as a potential cancer therapy. Ag5 damages mitochondrial function via elevated levels of reactive oxygen species (ROS). Considering that GBM and GSCs are characterized by high ROS levels and that Ag5 can easily cross the BBB, Ag5 harbours therapeutic potential in GBM. In preliminary experiments, we found that several patient-derived models of newly diagnosed and recurrent GBM were sensitive to Ag5 exposure. Importantly, this effect can be further enhanced when combined with radiotherapy (RT), due to enhanced production of ROS. However, RT has previously been shown to profoundly affect the TME, enhancing tumour progression, resistance and recurrence. Considering the favourable toxicology profile of Ag5, the successful candidate will investigate its therapeutic and activity across GBM TME subtypes using in vitro and in vivo model systems combined with state-of-the-art (spatial) single-cell profiling.

Expected secondments:

- 3 months (non-academic) to Arjuna Therapeutics S.L, A Coruña, Spain.

Specific requirements:

- MSc in Bio-engineering, Biomedical sciences or alike, preferentially with a solid foundation in bioinformatics.
- experience in (brain) tumour biology/oncology (*in vitro* and *in vivo* model experience are a major asset)
- Experience in (spatial) single-cell analysis
- Fluent written and spoken English, excellent oral communication skills and organizational skills. Interest in entrepreneurship and interaction of science and business. Interest and experience in online promotion of scientific products and knowledge, including experience in social media channels management.

EU salary budget: Living allowance - €122,400; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: Salary details will be provided anon. Please note that employee compulsory national contributions will be deducted from this amount.

Project 10: Novel combination approaches of targeted alpha therapies in GBM TME subtypes

Recruitment Location: Bayer AG, Berlin, Germany

Main Supervisor: Dr Oliver Politz, Principal scientist, Bayer AG, Research & Development, (Pharmaceuticals) (oliver.politz@bayer.com)

Co-supervisors: Prof Dr Konrad Klinghammer (Charité - Universitätsmedizin, Berlin, Germany), Prof Annette Byrne (RCSI)

Project Summary: Targeted alpha therapies (TAT) has emerged as a promising modality in oncology. Following systemic administration, TAT accumulates and delivers high linear energy transfer (LET) alpha particles directly to the tumour and TME with minimal damage to the surrounding healthy tissue. No mechanisms of resistance have been identified. DR10 will identify novel IDHwt specific GBM TAT targets and establish a novel precision medicine combinatorial TAT approach based on the TME subtypes.

Expected secondments:

- 4 months (academic) to RCSI, Dublin, Ireland.

Specific requirements:

- MSc in a Biological Discipline with preference given to those candidates with experience in Tumour Biology/Oncology/Immunology.
- Applicants with first experience in handling biologic molecules such as therapeutic antibodies and willingness to work with radioactivity (alpha emitter) would be preferred.
- Experience with Molecular biology, Cell culture, Flow cytometry methods and analysis.
- Experience with in vitro tumor modelling as well as omics data analysis and bioinformatics is a plus.

EU salary budget: Living allowance - €120,319.20; Mobility allowance - €21,600.

Expected gross annual salary of the doctoral candidate, following employer deductions and not including family allowance: Salary details will be provided anon. Please note that employee compulsory national contributions will be deducted from this amount.